Inhalationally Administered Semifluorinated Alkanes (SFAs) as Drug Carriers in an Experimental Model of Acute Respiratory Distress Syndrome
Aerosol therapy in patients suffering from acute respiratory distress syndrome (ARDS) has so far failed in improving patients’ outcomes. This might be because dependent lung areas cannot be reached by conventional aerosols. Due to their physicochemical properties, semifluorinated alkanes (SFAs) coul...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/3/431 |
id |
doaj-dcaed9d535624e1cb6ef426fec5fac28 |
---|---|
record_format |
Article |
spelling |
doaj-dcaed9d535624e1cb6ef426fec5fac282021-03-24T00:03:38ZengMDPI AGPharmaceutics1999-49232021-03-011343143110.3390/pharmaceutics13030431Inhalationally Administered Semifluorinated Alkanes (SFAs) as Drug Carriers in an Experimental Model of Acute Respiratory Distress SyndromeMatthias Otto0Jörg Krebs1Peter Welker2René Holm3Manfred Thiel4Luciano Gattinoni5Michael Quintel6Charalambos Tsagogiorgas7Department of Anaesthesiology and Critical Care Medicine, University Hospital Mannheim, Faculty of Medicine, University of Heidelberg, Theodor-Kutzer Ufer 1-3, 68165 Mannheim, GermanyDepartment of Anaesthesiology and Critical Care Medicine, University Hospital Mannheim, Faculty of Medicine, University of Heidelberg, Theodor-Kutzer Ufer 1-3, 68165 Mannheim, GermanyDepartment of Anaesthesiology and Critical Care Medicine, University Hospital Mannheim, Faculty of Medicine, University of Heidelberg, Theodor-Kutzer Ufer 1-3, 68165 Mannheim, GermanyDrug Product Development, Janssen Research and Development, Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, BelgiumDepartment of Anaesthesiology and Critical Care Medicine, University Hospital Mannheim, Faculty of Medicine, University of Heidelberg, Theodor-Kutzer Ufer 1-3, 68165 Mannheim, GermanyDepartment of Anesthesiology, Emergency and Intensive Care Medicine, University of Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, GermanyDepartment of Anesthesiology, Emergency and Intensive Care Medicine, University of Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, GermanyDepartment of Anaesthesiology and Critical Care Medicine, University Hospital Mannheim, Faculty of Medicine, University of Heidelberg, Theodor-Kutzer Ufer 1-3, 68165 Mannheim, GermanyAerosol therapy in patients suffering from acute respiratory distress syndrome (ARDS) has so far failed in improving patients’ outcomes. This might be because dependent lung areas cannot be reached by conventional aerosols. Due to their physicochemical properties, semifluorinated alkanes (SFAs) could address this problem. After induction of ARDS, 26 pigs were randomized into three groups: (1) control (Sham), (2) perfluorohexyloctane (F6H8), and (3) F6H8-ibuprofen. Using a nebulization catheter, (2) received 1 mL/kg F6H8 while (3) received 1 mL/kg F6H8 with 6 mg/mL ibuprofen. Ibuprofen plasma and lung tissue concentration, bronchoalveolar lavage (BAL) fluid concentration of TNF-α, IL-8, and IL-6, and lung mechanics were measured. The ibuprofen concentration was equally distributed to the dependent parts of the right lungs. Pharmacokinetic data demonstrated systemic absorption of ibuprofen proofing a transport across the alveolo-capillary membrane. A significantly lower TNF-α concentration was observed in (2) and (3) when compared to the control group (1). There were no significant differences in IL-8 and IL-6 concentrations and lung mechanics. F6H8 aerosol seemed to be a suitable carrier for pulmonary drug delivery to dependent ARDS lung regions without having negative effects on lung mechanics.https://www.mdpi.com/1999-4923/13/3/431fluorocarbonsaerosolsdrug carriersinhalationrespiratory distress syndrometissue distribution |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Matthias Otto Jörg Krebs Peter Welker René Holm Manfred Thiel Luciano Gattinoni Michael Quintel Charalambos Tsagogiorgas |
spellingShingle |
Matthias Otto Jörg Krebs Peter Welker René Holm Manfred Thiel Luciano Gattinoni Michael Quintel Charalambos Tsagogiorgas Inhalationally Administered Semifluorinated Alkanes (SFAs) as Drug Carriers in an Experimental Model of Acute Respiratory Distress Syndrome Pharmaceutics fluorocarbons aerosols drug carriers inhalation respiratory distress syndrome tissue distribution |
author_facet |
Matthias Otto Jörg Krebs Peter Welker René Holm Manfred Thiel Luciano Gattinoni Michael Quintel Charalambos Tsagogiorgas |
author_sort |
Matthias Otto |
title |
Inhalationally Administered Semifluorinated Alkanes (SFAs) as Drug Carriers in an Experimental Model of Acute Respiratory Distress Syndrome |
title_short |
Inhalationally Administered Semifluorinated Alkanes (SFAs) as Drug Carriers in an Experimental Model of Acute Respiratory Distress Syndrome |
title_full |
Inhalationally Administered Semifluorinated Alkanes (SFAs) as Drug Carriers in an Experimental Model of Acute Respiratory Distress Syndrome |
title_fullStr |
Inhalationally Administered Semifluorinated Alkanes (SFAs) as Drug Carriers in an Experimental Model of Acute Respiratory Distress Syndrome |
title_full_unstemmed |
Inhalationally Administered Semifluorinated Alkanes (SFAs) as Drug Carriers in an Experimental Model of Acute Respiratory Distress Syndrome |
title_sort |
inhalationally administered semifluorinated alkanes (sfas) as drug carriers in an experimental model of acute respiratory distress syndrome |
publisher |
MDPI AG |
series |
Pharmaceutics |
issn |
1999-4923 |
publishDate |
2021-03-01 |
description |
Aerosol therapy in patients suffering from acute respiratory distress syndrome (ARDS) has so far failed in improving patients’ outcomes. This might be because dependent lung areas cannot be reached by conventional aerosols. Due to their physicochemical properties, semifluorinated alkanes (SFAs) could address this problem. After induction of ARDS, 26 pigs were randomized into three groups: (1) control (Sham), (2) perfluorohexyloctane (F6H8), and (3) F6H8-ibuprofen. Using a nebulization catheter, (2) received 1 mL/kg F6H8 while (3) received 1 mL/kg F6H8 with 6 mg/mL ibuprofen. Ibuprofen plasma and lung tissue concentration, bronchoalveolar lavage (BAL) fluid concentration of TNF-α, IL-8, and IL-6, and lung mechanics were measured. The ibuprofen concentration was equally distributed to the dependent parts of the right lungs. Pharmacokinetic data demonstrated systemic absorption of ibuprofen proofing a transport across the alveolo-capillary membrane. A significantly lower TNF-α concentration was observed in (2) and (3) when compared to the control group (1). There were no significant differences in IL-8 and IL-6 concentrations and lung mechanics. F6H8 aerosol seemed to be a suitable carrier for pulmonary drug delivery to dependent ARDS lung regions without having negative effects on lung mechanics. |
topic |
fluorocarbons aerosols drug carriers inhalation respiratory distress syndrome tissue distribution |
url |
https://www.mdpi.com/1999-4923/13/3/431 |
work_keys_str_mv |
AT matthiasotto inhalationallyadministeredsemifluorinatedalkanessfasasdrugcarriersinanexperimentalmodelofacuterespiratorydistresssyndrome AT jorgkrebs inhalationallyadministeredsemifluorinatedalkanessfasasdrugcarriersinanexperimentalmodelofacuterespiratorydistresssyndrome AT peterwelker inhalationallyadministeredsemifluorinatedalkanessfasasdrugcarriersinanexperimentalmodelofacuterespiratorydistresssyndrome AT reneholm inhalationallyadministeredsemifluorinatedalkanessfasasdrugcarriersinanexperimentalmodelofacuterespiratorydistresssyndrome AT manfredthiel inhalationallyadministeredsemifluorinatedalkanessfasasdrugcarriersinanexperimentalmodelofacuterespiratorydistresssyndrome AT lucianogattinoni inhalationallyadministeredsemifluorinatedalkanessfasasdrugcarriersinanexperimentalmodelofacuterespiratorydistresssyndrome AT michaelquintel inhalationallyadministeredsemifluorinatedalkanessfasasdrugcarriersinanexperimentalmodelofacuterespiratorydistresssyndrome AT charalambostsagogiorgas inhalationallyadministeredsemifluorinatedalkanessfasasdrugcarriersinanexperimentalmodelofacuterespiratorydistresssyndrome |
_version_ |
1724205548464766976 |